High-sensitivity assay for monitoring ESR1 mutations in circulating cell-free DNA of breast cancer patients receiving endocrine therapy

Approximately 70% of breast cancers (BCs) express estrogen receptor alpha (ERα) and are treated with endocrine therapy. However, the effectiveness of this therapy is limited by innate or acquired resistance in approximately one-third of patients. Activating mutations in the ESR1 gene that encodes ER...

Descripción completa

Detalles Bibliográficos
Autores principales: Lupini, Laura, Moretti, Anna, Bassi, Cristian, Schirone, Alessio, Pedriali, Massimo, Querzoli, Patrizia, Roncarati, Roberta, Frassoldati, Antonio, Negrini, Massimo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5847549/
https://www.ncbi.nlm.nih.gov/pubmed/29531247
http://dx.doi.org/10.1038/s41598-018-22312-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5847549/
https://www.ncbi.nlm.nih.gov/pubmed/29531247
http://dx.doi.org/10.1038/s41598-018-22312-x

Ejemplares similares